Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 5/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11349824 | 0.82 | SMN1; SMN2 (0.48) | ALDH1A1MAPTRAB9AL3MBTL1ATM | |
| SCHEMBL1177958 | 0.81 | ATM (0.54) | ALDH1A1MAPTRAB9AL3MBTL1ATM | |
| SCHEMBL1178772 | 0.80 | TSHR (0.46) | ALDH1A1MAPTRAB9ATDP1L3MBTL1 | |
| SCHEMBL1179905 | 0.79 | TSHR (0.45) | ALDH1A1MAPTRAB9ATDP1L3MBTL1 | |
| SCHEMBL1178781 | 0.79 | TSHR (0.45) | ALDH1A1MAPTRAB9ATDP1L3MBTL1 | |
| SCHEMBL1178125 | 0.78 | POLB (0.46) | ALDH1A1RAB9AL3MBTL1ATMTSHR | |
| SCHEMBL11348223 | 0.75 | MAPK1 (0.58) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4206022 | 0.74 | LMNA (0.47) | MAPTRAB9AL3MBTL1ATMTSHR | |
| SCHEMBL11751742 | 0.74 | GAA (0.55) | ALDH1A1MAPTRAB9ATDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4211382 | 0.72 | ALDH1A1 (0.56) | ALDH1A1RAB9AL3MBTL1ATMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0001947-B1 | 2-AMINO-THIAZOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | INSTITUT MERIEUX (FR) | 1981-10-14 | — | — | EP | claimed |
| EP-2459542-B1 | Substituted N-benzyl-4,5-dihydrooxazol-2-amines useful as selective alpha 2B/2C receptor agonists | ALLERGAN INC (US) | 2014-10-29 | — | — | EP | disclosed |
| EP-2459542-B1 | Substituted N-benzyl-4,5-dihydrooxazol-2-amines useful as selective alpha 2B/2C receptor agonists | ALLERGAN INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8329918-B2 | Selective alpha 2B/2C agonists | ALLERGAN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329918-B2 | Selective alpha 2B/2C agonists | ALLERGAN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329918-B2 | Selective alpha 2B/2C agonists | ALLERGAN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2459542-A1 | SELECTIVE ALPHA 2B/2C AGONISTS | Allergan, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ALLERGAN, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ALLERGAN, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ALLERGAN, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2011014332-A1 | SELECTIVE ALPHA 2B/2C AGONISTS | ALLERGAN, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011014332-A1 | SELECTIVE ALPHA 2B/2C AGONISTS | ALLERGAN, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ADRA2C, ADRA2B, ADRB2 | ALDH1A1 1015/4885MAPT 3786/4885RAB9A 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.